Novel Biomarkers of Habitual Alcohol Intake and Associations With Risk of Pancreatic and Liver Cancers and Liver Disease Mortality.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
02 11 2021
02 11 2021
Historique:
accepted:
09
04
2021
received:
13
10
2020
revised:
24
02
2021
pubmed:
20
5
2021
medline:
25
2
2022
entrez:
19
5
2021
Statut:
ppublish
Résumé
Alcohol is an established risk factor for several cancers, but modest alcohol-cancer associations may be missed because of measurement error in self-reported assessments. Biomarkers of habitual alcohol intake may provide novel insight into the relationship between alcohol and cancer risk. Untargeted metabolomics was used to identify metabolites correlated with self-reported habitual alcohol intake in a discovery dataset from the European Prospective Investigation into Cancer and Nutrition (EPIC; n = 454). Statistically significant correlations were tested in independent datasets of controls from case-control studies nested within EPIC (n = 280) and the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC; n = 438) study. Conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations of alcohol-associated metabolites and self-reported alcohol intake with risk of pancreatic cancer, hepatocellular carcinoma (HCC), liver cancer, and liver disease mortality in the contributing studies. Two metabolites displayed a dose-response association with self-reported alcohol intake: 2-hydroxy-3-methylbutyric acid and an unidentified compound. A 1-SD (log2) increase in levels of 2-hydroxy-3-methylbutyric acid was associated with risk of HCC (OR = 2.54, 95% CI = 1.51 to 4.27) and pancreatic cancer (OR = 1.43, 95% CI = 1.03 to 1.99) in EPIC and liver cancer (OR = 2.00, 95% CI = 1.44 to 2.77) and liver disease mortality (OR = 2.16, 95% CI = 1.63 to 2.86) in ATBC. Conversely, a 1-SD (log2) increase in questionnaire-derived alcohol intake was not associated with HCC or pancreatic cancer in EPIC or liver cancer in ATBC but was associated with liver disease mortality (OR = 2.19, 95% CI = 1.60 to 2.98) in ATBC. 2-hydroxy-3-methylbutyric acid is a candidate biomarker of habitual alcohol intake that may advance the study of alcohol and cancer risk in population-based studies.
Sections du résumé
BACKGROUND
Alcohol is an established risk factor for several cancers, but modest alcohol-cancer associations may be missed because of measurement error in self-reported assessments. Biomarkers of habitual alcohol intake may provide novel insight into the relationship between alcohol and cancer risk.
METHODS
Untargeted metabolomics was used to identify metabolites correlated with self-reported habitual alcohol intake in a discovery dataset from the European Prospective Investigation into Cancer and Nutrition (EPIC; n = 454). Statistically significant correlations were tested in independent datasets of controls from case-control studies nested within EPIC (n = 280) and the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC; n = 438) study. Conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations of alcohol-associated metabolites and self-reported alcohol intake with risk of pancreatic cancer, hepatocellular carcinoma (HCC), liver cancer, and liver disease mortality in the contributing studies.
RESULTS
Two metabolites displayed a dose-response association with self-reported alcohol intake: 2-hydroxy-3-methylbutyric acid and an unidentified compound. A 1-SD (log2) increase in levels of 2-hydroxy-3-methylbutyric acid was associated with risk of HCC (OR = 2.54, 95% CI = 1.51 to 4.27) and pancreatic cancer (OR = 1.43, 95% CI = 1.03 to 1.99) in EPIC and liver cancer (OR = 2.00, 95% CI = 1.44 to 2.77) and liver disease mortality (OR = 2.16, 95% CI = 1.63 to 2.86) in ATBC. Conversely, a 1-SD (log2) increase in questionnaire-derived alcohol intake was not associated with HCC or pancreatic cancer in EPIC or liver cancer in ATBC but was associated with liver disease mortality (OR = 2.19, 95% CI = 1.60 to 2.98) in ATBC.
CONCLUSIONS
2-hydroxy-3-methylbutyric acid is a candidate biomarker of habitual alcohol intake that may advance the study of alcohol and cancer risk in population-based studies.
Identifiants
pubmed: 34010397
pii: 6278357
doi: 10.1093/jnci/djab078
pmc: PMC8562969
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1542-1550Subventions
Organisme : Medical Research Council
ID : MR/M012190/1
Pays : United Kingdom
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
PLoS One. 2016 Jun 29;11(6):e0158568
pubmed: 27355821
Int J Epidemiol. 1997;26 Suppl 1:S26-36
pubmed: 9126531
Am J Clin Nutr. 2014 Jun;99(6):1286-308
pubmed: 24760973
Alcohol Res Health. 2004-2005;28(1):30-7
pubmed: 19006989
Public Health Nutr. 2002 Dec;5(6B):1113-24
pubmed: 12639222
BMC Bioinformatics. 2018 Apr 20;19(1):151
pubmed: 29678131
Environ Res. 2019 Feb;169:417-433
pubmed: 30529143
Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):631-40
pubmed: 23396963
Bioinformatics. 2015 Mar 1;31(5):788-90
pubmed: 25348215
Nat Genet. 2014 Jun;46(6):543-550
pubmed: 24816252
Int J Cancer. 2018 Aug 15;143(4):801-812
pubmed: 29524225
Am J Clin Nutr. 2014 Jul;100(1):208-17
pubmed: 24740205
Br J Cancer. 2013 Sep 3;109(5):1344-51
pubmed: 23880821
Clin Epigenetics. 2018 Mar 21;10:38
pubmed: 29588806
Indian J Clin Biochem. 2005 Jan;20(1):35-42
pubmed: 23105491
Ther Drug Monit. 2005 Dec;27(6):747-51
pubmed: 16404815
Int J Epidemiol. 2016 Oct;45(5):1493-1506
pubmed: 27494945
Eur J Clin Nutr. 2000 Dec;54(12):900-17
pubmed: 11114689
Am J Clin Nutr. 2017 Aug;106(2):637-649
pubmed: 28659298
IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt E):1-538
pubmed: 23193840
Biosci Biotechnol Biochem. 2008 Feb;72(2):393-7
pubmed: 18256507
Am J Epidemiol. 2003 Jul 1;158(1):14-21; discussion 22-6
pubmed: 12835281
Br J Nutr. 2001 May;85(5):621-7
pubmed: 11348578
Am J Clin Nutr. 2014 Jun;99(6):1470-8
pubmed: 24760976
Anal Chem. 2019 Mar 5;91(5):3590-3596
pubmed: 30758187
Am J Clin Nutr. 2016 Sep;104(3):776-89
pubmed: 27510537
PLoS One. 2013 Oct 28;8(10):e78156
pubmed: 24205137
J Natl Cancer Inst. 2020 Mar 1;112(3):286-294
pubmed: 31168595
Nucleic Acids Res. 2018 Jan 4;46(D1):D608-D617
pubmed: 29140435
Circ Cardiovasc Genet. 2016 Dec;9(6):487-494
pubmed: 27784734
Altern Med Rev. 2008 Sep;13(3):205-15
pubmed: 18950247
Cancer Causes Control. 2014 Jun;25(6):693-9
pubmed: 24692102
Lancet. 2018 Sep 22;392(10152):1015-1035
pubmed: 30146330
J Proteomics. 2016 Sep 16;147:3-20
pubmed: 27130534
Metabolomics. 2018 Sep 20;14(10):128
pubmed: 30830398
Biochim Biophys Acta. 2003 Jul 21;1633(2):84-9
pubmed: 12880867
Clin Chim Acta. 2011 Jul 15;412(15-16):1428-35
pubmed: 21531215
Alcohol Alcohol. 2019 May 1;54(3):251-257
pubmed: 30968936
J Natl Cancer Inst. 2011 Nov 16;103(22):1686-95
pubmed: 22021666
Int J Cancer. 2021 Feb 1;148(3):609-625
pubmed: 32734650
Ann Epidemiol. 1994 Jan;4(1):1-10
pubmed: 8205268
Transl Psychiatry. 2013 Jul 02;3:e276
pubmed: 23820610
Environ Health Prev Med. 2016 Jan;21(1):18-26
pubmed: 26459263
Expert Rev Proteomics. 2012 Aug;9(4):425-36
pubmed: 22967079
Am J Clin Nutr. 2015 Oct;102(4):905-13
pubmed: 26269369
Int J Cancer. 2016 Jan 15;138(2):348-60
pubmed: 26238458
Mol Nutr Food Res. 2019 Nov;63(22):e1900659
pubmed: 31483556
Nutrients. 2018 May 22;10(5):
pubmed: 29789452
Am J Epidemiol. 2011 Sep 1;174(5):591-603
pubmed: 21765003
Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):784-95
pubmed: 12917211
Cancer Causes Control. 2009 Jul;20(5):785-94
pubmed: 19145468
Alcohol Clin Exp Res. 2015 Nov;39(11):2200-8
pubmed: 26503066
Indian J Clin Biochem. 2003 Jul;18(2):111-8
pubmed: 23105401